Centers for Medicare & Medicaid Services (CMS): Next Generation ACO Model
The Next Generation Accountable Care Organization (ACO) model is a reimbursement model for healthcare providers that aims to incentivize cost savings and improved patient outcomes. It builds upon the original Medicare Shared Savings Program (MSSP) ACO model, but with a greater emphasis on financial risk and performance-based payments. The Next Generation ACO model includes a higher minimum savings rate, an increased focus on care coordination, and the option for providers to assume downside financial risk. The goal of this model is to improve the quality of care for patients while also reducing costs for the healthcare system.
Know anyone building innovative solutions that belong in this 'Next Generation ACO Model'?
Join ICNGN 2023, a conference on intelligent computing and next-generation networks, in Hangzhou, China, on November 17-18. Engage with technical papers, keynotes, panels, and poster presentations. Accepted papers will be published in IEEE Xplore and reviewed by indexing companies like EI Compendex and Scopus. This event aims to foster cooperation, scientific exchanges, and technological progress in the field. Explore topics including next-generation networks, communications systems, and machine intelligence. Contact Amy Chen for more information.
The 4th Annual MarketsandMarkets Orphan Drugs and Rare Diseases Conference, scheduled for October 9–10 in London, United Kingdom ,aims to provide a valuable and broad platform to discuss recent advances in the development of life-saving therapies, critical issues, and strategies to enhance orphan drug development in near future. The conference will bring together scientists, researchers, entrepreneurs, academicians, medical officials, and technologists across the globe to discuss the newest findings in the areas of rare diseases and orphan drugs, helping to shape present and upcoming challenges in drug analysis. It gives participants the chance to interact with industry peers and participate in this scientific conference while staying informed about the most recent developments in the study of rare diseases.
Current landscape of Orphan Drugs across the globe.
Latest Developments in Orphan drug regulations in Europe.
Next Generation therapies treating uncommon/rare infections.
Practices to enhance access to patient data.
Clinical development & regulatory.
Digital health and Artificial intelligence.
Existing roadblocks in orphan drug development.
Patient Advocacy groups and their role in market access
Pricing and marketing plans for orphan medications.
The assurance cookie is found and is being filtered in Google Analytics.
These cookies are used to collect information about how you interact
with our website and allow us to remember you. We use this
information in order to improve and customize your browsing
experience, and for analytics and metrics about our visitors both on
this website and other media. To find out more about the cookies we
use, see our